PDF(Pubmed)
Abstract：
Systemic chemotherapy is the main treatment option for patients with advanced intrahepatic cholangiocarcinoma (iCCA), however, its efficacy is limited. Herein, we report a young patient with NRAS-mutated chemoresistant metastatic iCCA, who received second-line therapy with a combination of trametinib (MEK1/2 inhibitor), hydroxychloroquine (autophagy inhibitor), and bevacizumab (angiogenesis inhibitor). A significant response was achieved during therapy, resulting in a 25% decrease in the size of tumor lesions after 2 months of treatment and an improvement in the patient\'s condition. The duration of this response was 4 months, but the patient died 10 months after the initiation of this triple therapy. This case report and the analysis of other available studies warrant further investigations on combined MEK and autophagy inhibition in RAS-mutated tumors.
摘要：
全身化疗是晚期肝内胆管癌（iCCA）患者的主要治疗选择，然而,其功效有限。在这里，我们报告了一名NRAS突变的化学耐药转移性iCCA的年轻患者，谁接受二线治疗联合曲美替尼（MEK1/2抑制剂），羟氯喹（自噬抑制剂），和贝伐单抗（血管生成抑制剂）。在治疗期间取得了显著的反应，治疗2个月后肿瘤病灶大小减少25%，患者病情改善。这个反应的持续时间是4个月，但患者在三联疗法开始10个月后死亡。本病例报告和其他现有研究的分析需要进一步研究RAS突变肿瘤中MEK和自噬的联合抑制。
